Introduction
Bid (Boyd et al., 1995; Han et al., 1996; Wang,K. et al., 1996) , which interact with Bcl-2 and antagonize its Physiological cell death (apoptosis) (Kerr et al., 1972) is survival function. BH1 and BH2 of Bcl-2 are critical controlled by an intrinsic genetic program remarkably for heterodimerization with Bax and for promoting cell conserved in evolution (Ellis et al., 1991) and is essential survival (Yin et al., 1994) . In contrast, the BH3 domain for the proper development of the embryo, for maintaining of Bax, Bak, Bik and Bid is essential for their interaction tissue homeostasis and for host defense mechanisms. The with Bcl-2 and acceleration of apoptosis (Chittenden et al. , first intracellular regulator of apoptosis to be identified was 1995a; Hunter and Parslow, 1996; Wang,K. et al., 1996) . bcl-2 (Vaux et al., 1988) , the proto-oncogene commonly
It is now apparent that the BH1, BH2 and BH3 domains translocated to the Igh locus in human follicular lymphoma of Bcl-x L form an elongated hydrophobic cleft which can (Tsujimoto et al., 1984) . The Bcl-2 protein, which is bind BH3-containing peptides ; located on the cytosolic aspect of the nuclear envelope, Sattler et al., 1997) . Similarity between the three dimenthe endoplasmic reticulum and the outer membrane of sional structure of Bcl-x L and that of the pore-forming mitochondria, protects cells against diverse cytotoxic domains of certain bacterial toxins (Muchmore et al., insults (reviewed by Reed, 1994; Cory, 1995; Yang and 1996) has suggested that Bcl-2 proteins may form pores . Two close homologs, Bcl-x L (Boise in cytoplasmic membranes and regulate ion flux across et al., 1993) and Bcl-w (Gibson et al., 1996) , also promote them Minn et al., 1997) . cell survival, but more divergent members of the family, such as Bax (Oltvai et al., 1993) and Bak (Chittenden An intriguing aspect of Bcl-2 receiving increased atten-tion is its influence on the cell cycle. An early hint of a connection to cell cycle control was the quiescence of Bcl-2-expressing cells that survived cytokine withdrawal (Vaux et al., 1988) . It was subsequently noted that growth factor-starved cells were refractory to IL-3 stimulation of proliferation (Marvel et al., 1994) . More recently it has been shown by BrdU labeling that thymocyte turnover is slower in bcl-2 transgenic mice than in their littermate controls and that B and T cells expressing the transgene enter into the cell cycle more slowly than normal lymphocytes when stimulated with mitogens in vitro (Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., 1996 O'Reilly et al., , 1997a . In addition, quiescent NIH 3T3 fibroblasts expressing Bcl-2, Bcl-x L or their adenovirus counterpart, the E1B 19K protein, responded more slowly to serum stimulation (O'Reilly et al., 1996) . Bcl-2 has also been observed to hasten withdrawal from the cell cycle. Constitutive expression of Bcl-2 in HL60 cells had little effect on their proliferation or differentiation, but significantly accelerated their exit into G 0 in response to agents inducing differentiation (Vairo et al., 1996) . Thus, under certain conditions Bcl-2 favors quiescence over the cycling state.
To further understanding of Bcl-2 function, we have undertaken an extensive mutational analysis, focusing particularly on the conserved N-terminal BH4 region, which contains an amphipathic α-helix Lee et al., 1996) . We report here that a conserved tyrosine residue in this domain is required for Bcl-2 to inhibit cell cycle entry but is dispensable for its antiapoptotic activity. Mutation of the corresponding residue in Bcl-x L or Bcl-w had the same effect. This evidence raises the possibility that Bcl-2 and its close relatives exert at least two distinct functions in normal cellular survival, but not in those that enhance apoptosis ( Figure  1A ), raising the possibility that BH4 plays an important role in promoting cell survival. Consistent with this hypothesis, Bcl-2 deletion mutants lacking BH4 are unable firmed that the drug-resistant clones synthesized Bcl-2 to block apoptosis (Borner et al., 1994; Hunter et al., proteins of the expected size (see below). 1996; Lee et al., 1996 ; D.C.S.Huang, J.M.Adams and Multiple clones of transfected FDC-P1 cells were com-S.Cory, in preparation). As part of a mutagenesis screen pared for their ability to withstand three types of insult: of the BH4 region of Bcl-2 (D.C.S.Huang, J.M.Adams IL-3 deprivation, γ-irradiation or exposure to stauroand S.Cory, in preparation), we mutated the conserved sporine, a broad spectrum protein kinase inhibitor. Those Tyr28 to alanine, serine or phenylalanine. To test the expressing Y28 mutant Bcl-2 proteins were found to be functional consequence of these mutations, IL-3-dependent as resistant to these cytotoxic conditions as those promyelomonocytic FDC-P1 cells and B6.2.16BW2 T expressing wild-type Bcl-2 (Figure 2A-C) . Likewise, hybridoma cells were transfected with a vector co-B6.2.16BW2 T hybridoma cells expressing the wild-type expressing either wild-type or mutant human bcl-2 cDNA or mutant Bcl-2 proteins were equally protected from and a puromycin resistance gene. Since the degree of dexamethasone or γ-irradiation (not shown). We conclude protection from apoptosis afforded by Bcl-2 is proportional that, while the BH4 region is essential for inhibiting to its intracellular concentration (Huang et al., 1997) , the apoptosis (Borner et al., 1994; Hunter et al., 1996 ; puromycin-resistant clones were stained with anti-human D.C.S.Huang, J.M.Adams and S.Cory, in preparation), its Bcl-2 antibody and screened by flow cytometry to select conserved Y28 residue is not critical for this function, in those expressing similar levels of wild-type or mutant Bcl-2 (see for example Figure 1B ). Immunoblotting conagreement with recent observations (Lee et al., 1996) . 
Mutation of Y28 interferes with the ability of Bcl-2
The cell lines were then analyzed in more detail for their response to cytokine deprivation. In the absence of to restrain entry into the cell cycle We next addressed the effect of the Y28 mutation on the IL-3, FDC-P1 cells expressing high levels of Bcl-2 cease proliferating and enter a quiescent state in which they can ability of Bcl-2 to influence the cell cycle. We and others have previously shown that Bcl-2 and its functional remain viable for a prolonged period (Vaux et al., 1988) . Flow-cytometric analysis of cellular DNA content showed homologs do not affect the growth rate of continuously cycling cells (Fanidi et al., 1992; O'Reilly et al., 1996) , that the rate of exit from the cell cycle was comparable, irrespective of whether the cells expressed wild-type or although others have reported contrary findings (Borner, 1996; Mazel et al., 1996) . Multiple independent FDC-P1 Y28 mutant Bcl-2 ( Figure 3B ). A very significant difference became apparent, however, when we re-introduced clones were analyzed to determine whether the Y28 mutation had any effect on cell growth. No significant IL-3 into the cultures and compared their rates of re-entry into the cell cycle ( Figure 3C ). The cells expressing wilddifference could be discerned in either the proliferation rate or growth plateau of cells expressing Y28 mutant type Bcl-2 only entered the cycle after 5 days, but those expressing Y28 mutant Bcl-2 required only 2-3 days Bcl-2 compared with parental cells or those expressing wild-type Bcl-2 ( Figure 3A and data not shown).
( Figure 3C ). This difference was readily apparent for During exponential growth in the presence of IL-3, no differences could be discerned in the relative proportions of cells in different phases of the cell cycle for the parental line, transfectants expressing only the puromycin resistance gene and lines expressing either wild-type or Y28F Bcl-2 (see for example Figure 4 , top panels). When deprived of IL-3, only cells expressing wild-type or Y28 mutant Bcl-2 survived ( Figure 2A ) and, within 7 days, all of these had ceased cycling ( Figure 3B ) and entered G 0 (see for example Figure 4 , second panels). After readdition of IL-3, cycling eventually resumed, but cells expressing wild-type Bcl-2 took on average 2-3 days longer to enter G 1 and thence S phase than those expressing Y28F Bcl-2 (compare Figure 4 , third and fifth panels).
To extend these observations to a different cell type, we generated NIH 3T3 fibroblast lines expressing wildtype Bcl-2 or Y28 mutants. No difference could be detected in their proliferation rate in medium containing 10% serum (not shown). In medium lacking serum, the mutant proteins were just as effective at blocking apoptosis as wild-type Bcl-2 ( Figure 5A ). The cells ceased proliferating with the same kinetics ( Figure 5B ) and both arrested primarily in G 0 (Ͼ90%; not shown). When serum was added back after 7 days, cells expressing Y28 mutant Bcl-2 started cycling significantly sooner than those expressing wild-type Bcl-2 ( Figure 5C ). Three-color fluorescent staining for DNA, protein and RNA, performed as for FDC-P1 cells (Figure 4 ), suggests that this acceleration is from G 0 to G 1 (not shown). Taken together, these results show that Bcl-2 impedes entry into the cell cycle and that Y28 is required for this function.
Y28 mutant Bcl-2 has a dominant effect over wild-type Bcl-2
It was important to determine whether the Y28 mutant was dominant or recessive to wild-type Bcl-2 in its influence on cell cycle entry. To allow independent monitoring of mutant and wild-type Bcl-2 within the same cells, we utilized vectors expressing wild-type or mutant human Bcl-2 and FLAG-tagged wild-type mouse Bcl-2. FDC-P1 cells were transfected with each vector alone or in pairwise combinations and clones checked for appropriate expression of human or mouse Bcl-2 ( Figure 6A ). We first ascertained that FDC-P1 clones expressing FLAGtagged wild-type mouse Bcl-2 were resistant to apoptosis when deprived of IL-3 (not shown) and exhibited the Bcl-2 and their growth was indistinguishable from that of those expressing only the mutant protein ( Figure 6B ). Thus, Y28F mutant Bcl-2 is dominant and abrogates the multiple independent FDC-P1 clones expressing Y28A, Y28S or Y28F Bcl-2 (at least four of each) and also in cell cycle inhibitory effect of wild-type Bcl-2. polyclonal lines expressing these mutants.
In order to achieve better resolution of the different BH4 of Bcl-x L and Bcl-w contains a tyrosine residue functionally homologous to Y28 of Bcl-2 phases of the cycle, the kinetic analysis was repeated using three-color fluorescent staining for DNA, protein
Since the Bcl-2 homologs Bcl-x L and Bcl-w can also delay entry into the cell cycle (O'Reilly et al., 1996 ; and RNA content. Figure 4 displays the results for DNA versus protein content; equivalent results were apparent Table I ), we examined the consequence of replacing the equivalent BH4 tyrosine residue within these Bcl-2 when DNA was plotted versus RNA content (not shown). 5 . Wild-type, but not Y28 mutant, Bcl-2 delays entry of quiescent NIH 3T3 fibroblasts into the cell cycle. (A) Y28 mutant Bcl-2 proteins are as effective as wild-type Bcl-2 in inhibiting apoptosis of NIH 3T3 fibroblasts deprived of serum. Puromycin-resistant control transfected NIH 3T3 fibroblasts and clones expressing either wild-type or Y28 mutant Bcl-2 were cultured for 7 days in DME medium lacking serum and cell survival was determined by visual inspection under phase contrast. Data shown are arithmetic means Ϯ SD of at least three independent clones of each genotype representative of at least three experiments. (B) NIH 3T3 cells expressing wild-type and Y28 mutant Bcl-2 cease proliferating with similar kinetics when cultured in medium lacking serum. Entry into quiescence was determined by DNA and protein staining followed by flow-cytometric analysis. (C) NIH 3T3 cells expressing wild-type Bcl-2 are slower to re-enter the cell cycle than those expressing Y28 mutant Bcl-2. After 7 days of deprivation, 10% serum was added back to the cultures shown in (B) and cell cycle analysis performed at regular intervals by flow cytometry. The data shown are representative of experiments performed at least twice for more than three lines transfected with each construct.
homologs with phenylalanine. When deprived of IL-3, override the growth-inhibitory effect of p53 ( Figure 7B ). Thus, Y28 does not mediate the same function as the FDC-P1 clones expressing Y22F Bcl-x L or Y27F Bcl-w were as resistant to apoptosis as those expressing the region encompassed by amino acids 51-85, which forms part of the unstructured loop in Bcl-x L (Muchmore corresponding wild-type protein (Table I) . However, when IL-3 was added back to the cultures, cells expressing the et al., 1996) . mutant proteins resumed cycling much faster than those expressing comparable levels of the wild-type protein Tyr28 mutation does not prevent Bcl-2 association with known protein partners ( Table I) . The fact that a conserved tyrosine residue in BH4 displays comparable function for the three pro-
In an attempt to gain some insight into how Bcl-2 might influence cell cycle re-entry, we compared the ability of survival proteins argues that its inhibitory effect on the cell cycle is of physiological significance.
wild-type and Y28 mutant Bcl-2 to associate with other members of the wider Bcl-2 family. Wild-type or mutant Bcl-2 was co-expressed with FLAG-tagged Bax or Y28 Bcl-2 blocks apoptosis of p53-expressing cells but does not permit their proliferation GluGlu-tagged Bak, Bad (Yang et al., 1995) and Bik protein in L929 mouse fibroblast cells. Immune complexes We and others have previously shown that Bcl-2 blocks p53-induced apoptosis and that the surviving cells undergo were then isolated from cell lysates using anti-human Bcl-2 antibody. Immunoblotting of immunoprecipitated growth arrest (Selvakumaran et al., 1994; Strasser et al., 1994; Sabbatini et al., 1995; Wang,Y. et al., 1996) . material with anti-FLAG and anti-GluGlu antibodies demonstrated that the Y28 mutant was indistinguishable Recently it has been reported that baby rat kidney (BRK) cells expressing a mutant human Bcl-2 protein lacking from wild-type Bcl-2 in its ability to associate with Bax, Bak, Bad or Bik (Figure 8 ). Mutation of Y28 was also residues 51-85 of the non-conserved loop between BH4 and BH3 are not only resistant to p53-induced apoptosis shown not to affect the ability of Bcl-2 to homodimerize (not shown). Thus, the inability of Y28 mutant Bcl-2 but, unexpectedly, continue to proliferate (Uhlmann et al., 1996) . To assess whether Y28 mutant Bcl-2 might have proteins to inhibit cell cycle re-entry is not due to an inability to homodimerize or to interact with several family a similar effect, we transfected BRK cells bearing a temperature-sensitive mutant of p53 (Debbas and White, members known to promote apoptosis. 1993) with wild-type or Y28F Bcl-2 expression vectors and analyzed the proliferation and survival of cells at the R-Ras p23 does not mediate the effects of Bcl-2 on cell survival or the cell cycle permissive (32°C) and restrictive (38°C) temperatures. When p53 was in the mutant conformation (38°C), the R-Ras p23 is reported to bind to Bcl-2 (FernandezSarabia and Bischoff, 1993) and BHRF-1, the Epsteinparental cells and Bcl-2-expressing transfectants proliferated at the same rate and cell viability was high ( Figure  Barr homolog of Bcl-2 (Theodorakis et al., 1996) . Furthermore, a BHRF-1 mutant permissive for prolifera-7C and D). At 32°C, when p53 assumes its normal conformation, the parental cells died rapidly ( Figure 7A) . tion of cells expressing wild-type p53 had reduced capacity to bind to R-Ras p23 (Theodorakis et al., 1996) . These Bcl-2 Y28F inhibited p53-induced apoptosis as efficiently as wild-type Bcl-2 but, in contrast to the Bcl-2Δ51-85 observations led us to assess the capacity of wild-type and Y28 mutant Bcl-2 to interact with wild-type and mutant (Uhlmann et al., 1996) , the Y28F mutant did not of the R-Ras p23 proteins was confirmed by flow-cytometric analysis of permeabilized cells stained with the anti-GluGlu antibody and by immunoblotting. R-Ras p23 weakly facilitated apoptosis of FDC-P1 cells induced by cytokine deprivation ( Figure 9A ), consistent with a previous report (Wang,H.G. et al., 1995) . The activated G38V R-Ras mutant caused FDC-P1 cells to proliferate faster but did not result in IL-3 independence (not shown).
No association between wild-type or Y28 mutant Bcl-2 and any of the R-Ras p23 proteins could be detected in co-immunoprecipitation experiments (not shown). Furthermore, co-expression of Bcl-2 and wild-type (not shown), activating (G38V) or dominant negative (S43N) mutants of R-Ras p23 did not alter the anti-apoptotic activity of Bcl-2 ( Figure 9A ) or its effect in retarding entry into the cell cycle ( Figure 9B) . Therefore, at least in this cell type, it seems very unlikely that R-Ras p23 mediates the effect of Bcl-2 on either cell survival or cell cycle re-entry.
Discussion

Genetic separation of two functions of Bcl-2
The ability of Bcl-2 to promote cell survival is well established (Vaux et al., 1988; Cory, 1995; Korsmeyer, 1995; White, 1996) , but only recently has its influence on the cell cycle begun to attract scrutiny. In vitro Bcl-2-overexpressing cells that resist apoptosis when deprived factor (Marvel et al., 1994; O'Reilly et al., 1996) . In vivo in Eμ-bcl-2 transgenic mice are smaller than normal mutant human or mouse Bcl-2, as indicated, were cultured for 10 days in medium lacking IL-3, then re-stimulated by addition of IL-3.
resting B cells (Strasser et al., 1990) , and both B and T Samples were collected daily for cell cycle analysis by flow cytometry.
lymphoid cells expressing a bcl-2 transgene respond more Data shown are from representative experiments that were repeated at slowly to activation in vitro by mitogens and/or cytokines least twice; two other lines of the same genotype showed the same (Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., result. 1996). Bcl-x L , Bcl-w and the adenovirus E1B 19K protein restrain the re-activation of quiescent cells just as effectively as Bcl-2 (O'Reilly et al., 1996; this paper), so mutant R-Ras p23. FDC-P1 cells expressing wild-type or Y28 mutant Bcl-2 were transfected with vectors encoding the growth-inhibitory function of Bcl-2 may prove to be a general feature of the pro-survival subfamily of Bcl-2-GluGlu-tagged wild-type R-ras p23, G38V R-ras p23 (an activated mutant) (Cox et al., 1994; Saez et al., 1994) or related proteins.
The experiments described here demonstrate that the S43N R-ras p23 (a dominant negative mutant). Expression Fig. 7 . Wild-type and Y28 mutant Bcl-2 can inhibit p53-induced cell death. BRK cells expressing temperature-sensitive p53 (Debbas and White, 1993) were transfected with vectors encoding either wild-type or Y28F mutant Bcl-2; drug-resistant clones selected for comparable levels of Bcl-2 were cultured at the permissive (32°C) (A and B) or restrictive temperature (38°C) (C and D) and cell viability (A and C) and cell number (B and D) determined at regular intervals by phase contrast microscopy. The data shown are from a single experiment; a second experiment gave comparable results. Fig. 8 . Wild-type and Y28 mutant Bcl-2 can interact with Bax, Bak, Bad and Bik. Lysates containing similar levels of wild-type or Y28F mutant Bcl-2 as shown by immunoblotting (top) were immunoprecipitated with anti-human Bcl-2 monoclonal antibody. The immune complexes were resolved by SDS-PAGE and blotted using mouse anti-FLAG and anti-GluGlu antibodies followed by a rabbit anti-mouse IgG antibody and then probed with 125 I-conjugated staphylococcal protein A (bottom).
inhibitory action of Bcl-2 on cell cycle entry can be alanine, serine or phenylalanine did not affect the antiapoptotic activity of Bcl-2 but markedly reduced its ability genetically separated from its ability to promote cell survival. Mutation of a conserved tyrosine residue (Y28) to restrain re-entry of quiescent FDC-P1 myeloid cells or NIH 3T3 fibroblasts into the cell cycle upon exposure to at the C-terminal end of the BH4 homology region to cell cycle more rapidly. Since phenylalanine could not replace tyrosine at this position, an interesting possibility is phosphorylation at this site. To date, only serine phosphorylation of Bcl-2 has been reported (Haldar et al., 1995; Chen and Faller, 1996) , but tyrosine phosphorylation of Bcl-2 may occur when cells are quiescent or transiting from G 0 to G 1 . We are currently investigating posttranslational modification of Bcl-2 at different stages of the cell cycle.
Several proteins that bind to Bcl-2 and are therefore potential modulators of its cell cycle function have been screened for ability to interact with the Y28 mutants. Bax, Bak, Bad and Bik, all of which interfere with the antiapoptosis function of Bcl-2, bound in vivo to both the mutant and the wild-type protein (Figure 8) . By this criterion, none of these appears to be the putative protein partner that regulates cell cycle entry. R-Ras p23 seemed a particularly attractive candidate, since it has been reported to bind Bcl-2 in vitro (Fernandez-Sarabia and Bischoff, 1993) and to promote cellular transformation when overexpressed (Cox et al., 1994; Saez et al., 1994) . Furthermore, R-Ras p23 has been shown to bind in vivo to BHRF1, the Epstein-Barr virus homolog of Bcl-2, and mutant BHRF1 proteins defective in restraining cell cycling (see below) displayed reduced binding (Theodorakis et al., 1996) . However, we were unable to detect any physical interaction between Bcl-2 and R-Ras p23 in FDC-P1 cells. Furthermore, activating or dominant (Figure 9 ). Other protein partners that remain to be (A) cultured in the absence of IL-3 for 5 days and cell viability was tested include Bid (Wang,K. et al., 1996) , Raf-1 kinase assessed at daily intervals by visual inspection and vital dye exclusion. (Wang,H.G. et al., 1994) , Nip-1, Nip-2, Nip-3 (Boyd After 10 days, IL-3 was added to the cultures (B) and cell cycle analysis was performed at daily intervals. The data shown are et al., 1994), Bag-1 (Takayama et al., 1995) and 53BP2 representative of triplicate experiments; equivalent results were (Naumovski and Cleary, 1996) . obtained with three other lines of each genotype.
The phenotype of the Y28 mutant is distinct from that of other recently reported mutants of Bcl-2 and BHRF1 which exhibit reduced proliferation restraining function growth factors (Figures 3 and 5 ). Similar observations were made for analogous mutants of Bcl-x L (Y22F) and (Theodorakis et al., 1996; Uhlmann et al., 1996) . Expression of Bcl-2 or BHRF1 in BRK cells transformed with Bcl-w (Y27F).
The effect of Bcl-2 on the cell cycle appears to be a temperature-sensitive mutant of p53 and adenovirus E1A (Debbas and White, 1993) inhibits apoptosis normally tightly linked to its anti-apoptotic activity, since three inactivating mutations of Bcl-2 (G145E, W188A and provoked by incubation at the temperature permissive for wild-type p53 (Chiou et al., 1994; Theodorakis et al. , deletion of BH4) abrogate both activities and Bax, an antagonist of the anti-apoptotic activity of Bcl-2, can also 1996). Bcl-2 lacking much of the non-conserved loop (amino acids 51-85) located between BH4 and BH3 was counteract the cell cycle effect imposed by Bcl-2 (Borner, 1996; Brady et al., 1996; O'Reilly et al., 1996) . Thus the as effective as wild-type Bcl-2 in inhibiting p53-induced apoptosis of the transformed BRK cells, but rather than cell cycle control function of Bcl-2 appears to be distinct from, but dependent on, its anti-apoptotic function.
arresting their growth, permitted their continued proliferation (Uhlmann et al., 1996) . Similarly, a mutant BHRF1 It has been suggested that Bcl-2 inhibits cell cycle progression by lengthening the G 1 phase (Borner, 1996;  protein in which the YH at the beginning of BH3 (residues 50 and 51) had been replaced by AS was an effective Mazel et al., 1996) . However, we and others (Fanidi et al., 1992) have consistently found that overexpression of Bcl-2 inhibitor of p53-induced apoptosis and, unlike wild-type BHRF1, permitted cells to continue proliferating and its functional homologs does not affect the growth rate of cell lines cultured under optimal conditions but (Theodorakis et al., 1996) . In contrast to these mutations, mutation of Bcl-2 at Y28 does not prevent cells leaving only the rate at which cells transit from the quiescent G 0 state into the first S phase (O'Reilly et al., 1996;  Figure 3) . the cycle ( Figures 3B and 5B) ; it merely attenuates the ability of Bcl-2 to slow cell cycle re-entry (Figures 3C How might the C-terminal conserved tyrosine in the BH4 homology region of Bcl-2 and its homologs modulate and 5C). Nevertheless, our observations, taken together with those of Chinnadurai and colleagues (Theodorakis cell cycle activity? Post-translational modification of this residue may be essential for Bcl-2 to interact with a et al., 1996; Uhlmann et al., 1996) , implicate the region encompassing BH4-BH3 in the proliferation restraining protein that regulates the G 0 /G 1 transition and inability to form this complex may permit quiescent cells to enter the function of Bcl-2 and its homologs. Rosenberg, 1990 ) and the better prognosis of patients unless stated otherwise. whose breast cancer tissue shows abnormally high levels Cell lines were transfected by electroporation using a Gene-pulser of Bcl-2 expression (Lipponen et al., 1995) . It may also (BioRad) and selected by growth in puromycin (2-5 μg/ml) (Sigma), hygromycin (1-2 mg/ml) (Boehringer Mannheim) or both, depending account for the relatively low incidence of lymphomas in on the construct(s) transfected. Drug-resistant cell lines were cloned mice expressing a bcl-2 transgene in B and T lymphocytes using the cell deposition unit of a FACStarPlus (Becton Dickinson) or (McDonnell and Korsmeyer, 1991;  by limiting dilution culture. Clones expressing high levels of the protein Linette et al., 1995) , since lymphocytes from these animals of interest were identified by immunofluorescence staining of fixed and showed a slower turnover compared with control animals permeabilized cells followed by flow-cytometric analysis (see below). Cell death was induced by culturing the cells in the absence of (Linette et al., 1996; Mazel et al., 1996; cytokine (no IL-3 for FDC-P1 cells or no serum for NIH 3T3 fibroblasts) 1996, 1997a,b) .
Implications for the role of Bcl-2 in normal
or by treatment with 10 Gy γ-radiation (provided by a 60 Co source at a
The demonstration that the Y28 mutant is dominant in vivo would overcome the restraint on cycling normally excluded propidium iodide (5 μg/ml; Sigma) (Nicoletti et al., 1991) .
exercised by Bcl-2, while still inhibiting apoptosis. If so, Y28 mutant bcl-2 might be a more aggressive oncogene
Immunofluorescence, immunoprecipitation and than bcl-2, and we are currently testing this possibility.
immunoblotting Immunofluorescence staining of cytoplasmic proteins was performed as
Somatic mutations of the translocated bcl-2 gene have previously described (Strasser et al., 1995) . Briefly,~10 5 cells were been described (Tanaka et al., 1992; Matolcsy et al., 1996) fixed for 5 min in 80% methanol and permeabilized with 0.3% saponin and, intriguingly, in three out four cases of morphologically (Sigma) , which was included in all the subsequent steps. The cells were transformed follicular lymphoma, the mutations involve stained with~1 μg/ml of the monoclonal antibodies Bcl-2-100 (mouse anti-human Bcl-2; Pezzella et al., 1990) collaborating with adenovirus E1A to transform primary mouse L929 fibroblasts (7.5ϫ10 5 ) were co-transfected by lipofection BRK cells (Theodorakis et al., 1996) . Thus somatic using Lipofectamine ® (Gibco BRL) with vectors expressing wild-type mutation of survival promoting genes may contribute to bcl-2 or bcl-2 Y28F mutant and vectors expressing FLAG-tagged Bax tumor progression.
or GluGlu-tagged Bak, Bad and Bik. After 48 h the cells were harvested into 500 μl lysis buffer (20 mM Tris-HCl, pH 8, 135 mM NaCl, 1 mM
The realization that Bcl-2 can retard entry into the cell EGTA, 1% Triton X-100, 10% glycerol, 0.5 μg/ml Pefabloc, 1 μg/ml cycle also has implications for anti-cancer therapy. Since each leupeptin, aprotinin, soybean trypsin inhibitor and pepstatin, 5 mM most chemotherapeutic drugs target dividing cells, maligNaF and 2 mM Na 3 VO 4 ; reagents from Sigma or Boehringer Mannheim).
nant cells expressing Bcl-2 are 'doubly' protected: they 
Materials and methods
blue), resolved on a 4-20% polyacrylamide gel (Novex) and transferred to nitrocellulose membranes by electroblotting. After incubation overExpression constructs and site-directed mutagenesis night at 4°C in 5% skimmed milk, 1% casein and 0.05% Tween-20 to cDNAs were cloned into the expression vectors pEF PGKpuro (Huang prevent non-specific binding, the filter was incubated (1 h at room et al., 1997) or pEF PGKhygro (D.C.S.Huang, unpublished), both of temperature) with mouse anti-FLAG and anti-GluGlu antibodies which were developed from pEF BOS (Mizushima and Nagata, 1990) (~1 μg/ml) followed by 5 μg/ml affinity-purified rabbit anti-mouse IgG or derivatives thereof incorporating N-terminal FLAG (DYKDDDK) (Fcγ specific; Jackson Immuno Research). Membranes were then probed (Hopp et al., 1988) or GluGlu (EYPME) (Grussenmeyer et al., 1985) (1 h at room temperature) with 125 I-labeled staphylococcal protein A tags. The cDNAs for bcl-2, bcl-x L , bcl-w, bax, bak and R-ras p23 were (~2ϫ10 6 c.p.m./ml). Experiments to test for interactions between Bcl-2 gifts from M.Cleary, C.Thompson, L.Gibson, S.Korsmeyer, G.Evan and and R-Ras p23 were similarly performed on lysates derived from FDC-A.Hall respectively. The other cDNAs were generated by PCR from P1 cells that stably co-expressed Bcl-2 and the different forms of cDNA libraries and their sequence verified by automated sequencing.
R-Ras p23. Mutations of bcl-2, bcl-x L , bcl-w and R-ras p23 were generated by PCR via splice overlap extension (Horton et al., 1993) using the proof-reading Cell cycle analysis Pfu DNA polymerase (Stratagene); details of oligonucleotides used will
Prior to cell cycle analysis, FDC-P1 and NIH 3T3 clones were maintained be supplied on request. The sequences of derived clones were all verified in exponential growth by supplementing the cultures daily with excess by automated sequencing (ABI Perkin Elmer) prior to function analysis. culture medium. All cultures chosen for analysis were Ͼ95% viable immediately prior to withdrawal of IL-3 or serum. FDC-P1 cells (6ϫ10 6 ) were washed twice in DMEM containing 10% FCS but no IL-3 and Tissue culture and cell death analysis Cell lines used were FDC-P1, a mouse IL-3-dependent promyelomonoresuspended at a density of 2ϫ10 5 cells/ml. The NIH 3T3 clones were cultured at low density (Ͻ30% confluence) in medium lacking FCS. cytic cell line; B6.2.16BW2, a mouse T cell hybridoma; mouse fibroblastoid lines L929 [subline LM(-TK)] and NIH 3T3 (for references see Following 10-15 days growth factor deprivation, Bcl-2-expressing FDC-P1 or NIH 3T3 clones were harvested, counted and re-seeded at 2ϫ10 5 domain in Bak, distinct from BH1 and BH2, mediates cell death and cells/ml in medium containing 10% FCS plus 1000 U/ml IL-3 (FDC-P1 protein binding functions. 
